Stock Events

Stock Events

SAB Biotherapeutics 

$3.82
22
-$0.12-2.93% 18:58 Today

Statistics

Day High
3.95
Day Low
3.8
52W High
5.15
52W Low
1.85
Volume
136,087
Avg. Volume
674,382
Mkt Cap
347.11M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

17NovExpected
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q1 2026
Q2 2026
Next
-1.19
-0.86
-0.54
-0.21
Expected EPS
-0.274581
Actual EPS
N/A

Financials

-Profit Margin
Profitable
2020
2021
2022
2023
2024
2025
0Revenue
1.29MNet Income

Analyst Ratings

12.29Average Price Target
The highest estimate is 16.00.
From 7 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow SABS. It's not an investment recommendation.
Tesla
4
TSLA
NVIDIA
4
NVDA
Plug Power
4
PLUG
Apple
3
AAPL

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Regeneron Pharmaceuticals
REGN
Mkt Cap85.87B
Regeneron Pharmaceuticals competes in the development of monoclonal antibodies, a space SAB Biotherapeutics is also focusing on, particularly in immunotherapy treatments.
Adma Biologics
ADMA
Mkt Cap2.2B
ADMA Biologics is involved in the development, manufacturing, and marketing of specialty plasma-derived biologics, directly competing with SAB's platform for therapeutic proteins.
Novavax
NVAX
Mkt Cap1.47B
Novavax is a competitor due to its work on vaccines, including those for infectious diseases, a key area of focus for SAB Biotherapeutics.
Moderna
MRNA
Mkt Cap57.94B
Moderna is known for its mRNA technology but is expanding into other areas of infectious disease treatment and vaccine development, making it a competitor.
BioNTech
BNTX
Mkt Cap29.28B
BioNTech competes in the space of developing novel therapies, including mRNA-based vaccines, which could overlap with SAB's infectious disease focus.
Pfizer
PFE
Mkt Cap159.99B
Pfizer, with its broad range of vaccines and therapeutic agents, competes across several areas, including those targeted by SAB Biotherapeutics.
GSK
GSK
Mkt Cap104.97B
GlaxoSmithKline, with its extensive vaccine and therapeutic portfolio, competes in the immunotherapy and infectious disease space.
Sanofi
SNY
Mkt Cap109.86B
Sanofi operates in similar therapeutic areas, including vaccines and immune response treatments, making it a competitor.
Johnson & Johnson
JNJ
Mkt Cap651.25B
Johnson & Johnson, through its pharmaceutical division Janssen, competes in the development of vaccines and treatments for infectious diseases.
Astrazeneca
AZN
Mkt Cap257.42B
AstraZeneca is involved in the research and development of vaccines and treatments for various diseases, competing with SAB Biotherapeutics in the immunotherapy space.

About

SAB Biotherapeutics Inc is a clinical-stage biopharmaceutical company focused on developing multi-specific, high-potency, human immunoglobulin G (hIgG) to treat and prevent immune and autoimmune disorders. The company's lead product candidate, SAB-142, targets autoimmune Type 1 Diabetes (T1D) with a disease-modifying therapeutic approach that aims to change the T1D treatment paradigm by delaying onset and potentially preventing disease progression of Stage 3 T1D patients. It is focused on developing product candidates for disease targets where a differentiated approach has the greatest potential to be either first-in-class against novel targets against complex targets to treat diseases, including type 1 diabetes (T1D) and other autoimmune disorders.
Show more...
CEO
Samuel J. Reich
Employees
86
Country
Cayman Islands
ISIN
US78397T2024

Listings

XNAS
US
SABSW
XNAS
US
SABS
BOATS
BOATS
SABS.BOATS

0 Comments

Share your thoughts

FAQ

What is SAB Biotherapeutics stock price today?▼
The current price of SABS is $3.82 USD — it has decreased by -2.93% in the past 24 hours. Watch SAB Biotherapeutics stock price performance more closely on the chart.
What is SAB Biotherapeutics stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on XNAS exchange SAB Biotherapeutics stocks are traded under the ticker SABS.
Is SAB Biotherapeutics stock price growing?▼
SABS stock has risen by +0.93% compared to the previous week, the month change is a +10.58% rise, over the last year SAB Biotherapeutics has showed a +81.67% increase.
What is SAB Biotherapeutics market cap?▼
Today SAB Biotherapeutics has the market capitalization of 347.11M
When is the next SAB Biotherapeutics earnings date?▼
SAB Biotherapeutics is going to release the next earnings report on November 17, 2026.
What were SAB Biotherapeutics earnings last quarter?▼
SABS earnings for the last quarter are -0.28 USD per share, whereas the estimation was -0.28 USD resulting in a +1.06% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is SAB Biotherapeutics revenue for the last year?▼
SAB Biotherapeutics revenue for the last year amounts to 0 USD.
What is SAB Biotherapeutics net income for the last year?▼
SABS net income for the last year is 1.29M USD.
How many employees does SAB Biotherapeutics have?▼
As of August 28, 2026, the company has 86 employees.
In which sector is SAB Biotherapeutics located?▼
SAB Biotherapeutics operates in the Health & Wellness sector.
When did SAB Biotherapeutics complete a stock split?▼
The last stock split for SAB Biotherapeutics was on January 05, 2024 with a ratio of 1:10.
Where is SAB Biotherapeutics headquartered?▼
SAB Biotherapeutics is headquartered in MIAMI BEACH, Cayman Islands.